Treating COVID-19: are we missing out the window of opportunity?
J Antimicrob Chemother
; 76(2): 283-285, 2021 01 19.
Article
in English
| MEDLINE | ID: covidwho-889571
ABSTRACT
Severe COVID-19 is a biphasic illness, with an initial viral replication phase, followed by a cascade of inflammatory events. Progression to severe disease is predominantly a function of the inflammatory cascade, rather than viral replication per se. This understanding can be effectively translated to changing our approach in managing the disease. The natural course of disease offers us separate windows of specific time intervals to administer either antiviral or immunomodulatory therapy. Instituting the right attack at the right time would maximize the benefit of treatment. This concept must also be factored into studies that assess the efficacy of antivirals and immunomodulatory agents against COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Immunomodulation
/
Time-to-Treatment
/
COVID-19 Drug Treatment
/
Immunosuppressive Agents
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
J Antimicrob Chemother
Year:
2021
Document Type:
Article
Affiliation country:
Jac
Similar
MEDLINE
...
LILACS
LIS